Acute myeloid leukemia (AML) and Acute lymphocytic leukemia (ALL) – David Sallman, MD, and Robert Figlin, MD, discuss clinical highlights from ASH 2020

Acute myeloid leukemia (AML) and Acute lymphocytic leukemia (ALL) – David Sallman, MD, and Robert Figlin, MD, discuss clinical highlights from ASH 2020

Tuesday December 22, 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and David Sallman, MD, Assistant Member, Department of Malignant Hematology, Moffitt Cancer Center discuss CAR T as it pertains to clinical advances in leukemia

Breast Cancer – Sara Hurvitz, MD, and Robert Figlin, MD, discuss recent clinical developments in early stage and late stage breast cancer

Friday July 17, 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Sara Hurvitz, MD, Associate Professor of Medicine, Geffen School of Medicine, UCLA, Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit, discuss breast cancer patient types, challenges, and treatment advances.

Non Small Cell Lung Cancer (NSCLC) – Edward Garon, MD, and Robert Figlin, MD, discuss promising agents in development for the management of NSCLC from ASCO20

Thursday June 11, 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Edward Garon, MD, Director of Thoracic Oncology Program, Jonsson Comprehensive Cancer Center, Associate Professor of Medicine, David Geffen School of Medicine, UCLA, discuss promising agents in development for the management of NSCLC from ASCO20

Featured Videos

Priya Rastogi, MD, elaborates on the role of abemaciclib in HR+, HER2- node positive breast cancer

Rachna Shroff, MD, on the most promising pathways for targeted therapies in GI cancers

Adam Brufsky, MD, PhD, discusses results from the Phase III NALA study presented at SABCS 2020